Sequenom (SQNM) Kills All Hope
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Join SI Premium – FREE
The investors sentiment on Sequenom Inc. (Nasdaq: SQNM), following news that they completed an independent investigation related to test data for the noninvasive prenatal test for Trisomy 21 (Down syndrome), looks grim.
While investors wanted a clean house (executives terminated), there was not one positive from the release. This could re-open 50% or more lower.
The company reiterates that it is no longer relying on, and the public should no longer rely on, any of the previously announced test data and results for the company's noninvasive prenatal test for Trisomy 21.
While investors wanted a clean house (executives terminated), there was not one positive from the release. This could re-open 50% or more lower.
The company reiterates that it is no longer relying on, and the public should no longer rely on, any of the previously announced test data and results for the company's noninvasive prenatal test for Trisomy 21.
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Keenova doses first patient in Phase 3 hammer toe drug trial
- FDA grants Nuvation Bio fast track status for brain cancer drug
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
